ImmunoVaccine Inc. (CVE:IMV) – Investment analysts at National Bank Financial issued their FY2017 earnings per share estimates for ImmunoVaccine in a report released on Tuesday. National Bank Financial analyst E. Leno expects that the company will earn ($0.08) per share for the year. National Bank Financial also issued estimates for ImmunoVaccine’s FY2018 earnings at ($0.11) EPS and FY2019 earnings at ($0.04) EPS.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/08/11/analysts-set-expectations-for-immunovaccine-inc-s-fy2017-earnings-cveimv.html.

ImmunoVaccine (CVE:IMV) traded up 1.68% during mid-day trading on Friday, reaching $1.21. 5,960 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $1.21 and a 200-day moving average price of $1.21. The stock’s market cap is $145.81 million. ImmunoVaccine has a 52 week low of $0.56 and a 52 week high of $1.70.

About ImmunoVaccine

Immunovaccine Inc is a Canada-based clinical stage vaccine and immunotherapy company. The Company discovers and develops activators of the immune system to treat cancer and prevent infectious diseases. The Company’s DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system.

Receive News & Ratings for ImmunoVaccine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoVaccine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.